325 related articles for article (PubMed ID: 19910392)
1. The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Bonkowski J; Vermeulen LC; Kolesar JM
J Oncol Pharm Pract; 2010 Dec; 16(4):223-32. PubMed ID: 19910392
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide, a thalidomide derivative, shows promise in various applications.
Oestreicher P
ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
[No Abstract] [Full Text] [Related]
3. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
4. Role of lenalidomide in the treatment of myelodysplastic syndromes.
Komrokji RS; List AF
Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
[TBL] [Abstract][Full Text] [Related]
5. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
[No Abstract] [Full Text] [Related]
6. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Palumbo A; Freeman J; Weiss L; Fenaux P
Expert Opin Drug Saf; 2012 Jan; 11(1):107-20. PubMed ID: 22066855
[TBL] [Abstract][Full Text] [Related]
7. Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
Hadiji Mseddi S; Kallel F; Kassar O; Elloumi M; Jedidi I; Sennana H; Fenaux P
Leuk Res; 2011 Sep; 35(9):e175-6. PubMed ID: 21658768
[No Abstract] [Full Text] [Related]
8. Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.
Göhring G; Lange K; Hofmann W; Nielsen KV; Hellström-Lindberg E; Roy L; Morgan M; Kreipe H; Büsche G; Giagounidis A; Schlegelberger B
Leukemia; 2012 Feb; 26(2):356-8. PubMed ID: 21799512
[No Abstract] [Full Text] [Related]
9. Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome.
Melchert M; Williams C; List A
Leukemia; 2007 Jul; 21(7):1576-8. PubMed ID: 17392815
[No Abstract] [Full Text] [Related]
10. Lenalidomide (Revlimid) for anemia of myelodysplastic syndrome.
Med Lett Drugs Ther; 2006 Apr; 48(1232):31-2. PubMed ID: 16625140
[No Abstract] [Full Text] [Related]
11. Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
Cannella L; Latagliata R; Breccia M; Carmosino I; Loglisci G; Volpicelli P; Ferretti A; Santopietro M; Vozella F; Girmenia C; Cuzzola M; Oliva EN; Alimena G
Ann Hematol; 2012 Feb; 91(2):309-10. PubMed ID: 21625998
[No Abstract] [Full Text] [Related]
12. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
Melchert M; Kale V; List A
Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
[TBL] [Abstract][Full Text] [Related]
13. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.
Giagounidis AA; Kulasekararaj A; Germing U; Radkowski R; Haase S; Petersen P; Göhring G; Büsche G; Aul C; Mufti GJ; Platzbecker U
Leukemia; 2012 Apr; 26(4):855-8. PubMed ID: 21960245
[No Abstract] [Full Text] [Related]
14. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
Nomdedeu M; Maffioli M; Calvo X; Martínez-Trillos A; Baumann T; Díaz-Beyá M; Aguilar JL; Rozman M; Costa D; Esteve J; Cervantes F; Colomer D; Nomdedeu B
Leuk Res; 2011 Sep; 35(9):1276-8. PubMed ID: 21764129
[No Abstract] [Full Text] [Related]
15. Lenalidomide in myelodysplastic syndrome and multiple myeloma.
Shah SR; Tran TM
Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955
[TBL] [Abstract][Full Text] [Related]
16. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
[TBL] [Abstract][Full Text] [Related]
17. Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
Breccia M; Cannella L; Latagliata R; Nanni M; Santopietro M; Loglisci G; Ferretti A; Barzotti R; Oliva EN; Alimena G
Leuk Res; 2011 Jun; 35(6):e69-70. PubMed ID: 21232796
[No Abstract] [Full Text] [Related]
18. [The 5q- syndrome].
Adès L; Fenaux P
Rev Prat; 2010 Dec; 60(10):1420-2. PubMed ID: 21425544
[No Abstract] [Full Text] [Related]
19. Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series.
Coutinho R; Costa D; Carrió A; Muñoz C; Vidal A; Belkaid M; Campo E; Nomdedeu B
Ann Hematol; 2010 Oct; 89(10):1069-70. PubMed ID: 20232065
[No Abstract] [Full Text] [Related]
20. Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes.
Kurtin S; Sokol L
Cancer Control; 2006 Dec; 13 Suppl():26-31. PubMed ID: 17242664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]